The unified airway hypothesis: evidence from specific intervention with anti-IL-5 biologic therapy.

Bachert C, et al. J Allergy Clin Immunol Pract. 2023;11(9):2630-2641.

Epithelial cell alarmin cytokines: frontline mediators of the asthma inflammatory response.

Duchesne M, et al. Front Immunol. 2022;13:975914.

Type 2 inflammation in asthma and other airway diseases.

Maspero J, et al. ERJ Open Res. 2022;8(3):00576-2021.

The advance on pathophysiological mechanisms of type 2 chronic rhinosinusitis with nasal polyposis.

Yang C, et al. Front Allergy. 2025;6:1599797.

T2 biologics for chronic obstructive pulmonary disease.

Yousuf A, et al. J Allergy Clin Immunol Pract. 2019;7(5):1405-1416.

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

Corren J, et al. ERJ Open Res. 2026;12(1):00183-2025.

Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial.

Kelsen SG, et al. J Allergy Clin Immunol. 2021;148(3):790-798. 

Efficacy and safety of itepekimab in patients with moderate-to-severe asthma.

Wechsler ME, et al. N Engl J Med. 2021;385(18):1656-1668.

Tezepelumab in adults and adolescents with severe, uncontrolled asthma.

Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800-1809.

Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps.

Lipworth BJ, et al. N Engl J Med. 2025;392(12):1178-1188.

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.

Singh D, et al. Eur Respir J. 2025;66(1):2402231.

Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.

Rabe KF, et al. Lancet Respir Med. 2021;9(11):1288-1298.

Consensus summary on the definition of asthma remission.

Katial RK, et al. J Allergy Clin Immunol. 2025;156(3 suppl):S20-S24.

Consensus criteria for chronic rhinosinusitis disease control: an international Delphi study.

Sedaghat AR, et al. Rhinology. 2023;61(6):519-530.

ATS 2026 International Conference.

Online program.

Patient Advocacy Organizations and Resources 

Asthma and Allergy Foundation of America (AAFA)

AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research.

American Academy of Allergy, Asthma, & Immunology (AAAAI)

The AAAAI is the leading membership organization of more than 7100 allergists/immunologists and patients' trusted resource for allergies, asthma and immune deficiency disorders.  

American College of Allergy, Asthma, & Immunology (ACAAI)

The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.

American Lung Association

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research. 

American Thoracic Society (ATS)

The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.

Chest Foundation

The CHEST Foundation creates trusted patient education resources and disease awareness campaigns that empower patients to engage in better managing their health. 

COPD Foundation

The COPD Foundation’s mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease.